Clinical trials
Phase 1/2 COVID-19 trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
252 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2019 | 1 |
| 2020 | 116 |
| 2021 | 79 |
| 2022 | 30 |
| 2023 | 11 |
| 2024 | 7 |
| 2025 | 6 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 128 |
| Unknown status | 59 |
| Terminated | 26 |
| Withdrawn | 24 |
| Recruiting | 9 |
| Active, not recruiting | 4 |
| Not yet recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| BioNTech SE | 4 |
| Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 4 |
| Sinocelltech Ltd. | 4 |
| AnGes, Inc. | 3 |
| ImmunityBio, Inc. | 3 |
| Novavax | 3 |
| Stanford University | 3 |
| ANRS, Emerging Infectious Diseases | 2 |
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 2 |
| CanSino Biologics Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 252 |
| Coronavirus Infections | 37 |
| Respiratory Distress Syndrome | 24 |
| Pneumonia | 13 |
| Severe Acute Respiratory Syndrome | 11 |
| Virus Diseases | 10 |
| Pneumonia, Viral | 8 |
| Acute Lung Injury | 6 |
| Cytokine Release Syndrome | 6 |
| Lung Diseases | 5 |
Trials
Showing 51 to 75 of 252. Each trial links to its page on Pharma Observatory.
152 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.